retatrutide weight loss trial data just delivered the most powerful ever recorded in a Phase 3 obesity trial. At 104 weeks, participants on the 12 mg dose lost an average of 85 pounds 28.7% Weight Loss in New

This may explain SUMMITs more substantial effect on hard endpoints (38% risk reduction in heart-related outcomes)

Furthermore, the increasing awareness of the cardiovascular and renal benefits of GLP-1 receptor agonists is further driving their uptake in the region

Its not a synthetic drug its a natural, bio-optimized approach designed to enhance your bodys own GLP-1 response while supporting mood, metabolism, cellular repair, and long-term energy balance

Its common for symptoms to fluctuate in severity

Gastrointestinal effects Nausea is the most commonly reported side effect, especially during the first few weeks and after each dose increase

Past GLP-1 use (sema / tirz / none)